Dendreon may be on its last legs, but former CEO Mitchell Gold is happily entrenched in other projects: He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company through his investment firm, Alpine BioVentures.
It’ll be a recombinant protein-based therapeutic, Gold told MedCity News – and unrelated to the platform used by Dendreon. Beyond that, he’s keeping mum about the venture and will for a while, he said.
Two former Amgen scientists are also listed on an SEC filing announcing the fundraise: Michael Kornacker and Ryan Swanson, who both seem to have left their jobs in December. Kornacker’s work has been in antibody protein engineering, and Swanson’s on inflammation and T cell stimulation. Also heading up Alpine Immune Sciences – and the venture firm – is David Miller, a former analyst who now works as a portfolio manager.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Dendreon is known for launching Provenge, a prostate cancer drug that was the first-ever immunotherapy treatment to get regulatory approval. Dendreon’s also known for filing for bankruptcy this past November, because of the drug’s poor performance – it was too costly at $93,000 and required too much patient personalization. Also, importantly, the company couldn’t pay an enormous debt from 2011.
Gold left Dendreon in February 2012, after nine years as CEO – during which time he made some serious money, and gained some serious notoriety for some borderline bilking of investors. After Provenge got FDA approval, Gold made about $26.7 million – Dendreon’s stock was, after all, trading at more than $50 a share. These days, Dendreon’s below 20 cents a share – and is the target of a potential $400 million acquisition from Valeant.
Alpine BioVentures founded another biotech, called Alpine Biosciences, that was sold to Oncothyreon last August in a deal it said was valued at $27 million.